GlassScriptPhysician profile
Kelly B Cox
NPI 1356489264
$8,449.75
in general payments reported to CMS, 2019-2025
55 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,883 · 2022: $1,560 · 2023: $1,753 · 2024: $1,598 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,912 · Education: $94.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,911.92 |
| Education | $94.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $765.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $697.49 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $666.87 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $648.06 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.03 | 2021-2025 | Jardiance |
| Pfizer INC. | $636.03 | 2021-2025 | |
| Abbvie INC. | $524.07 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $399.01 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Novartis Pharmaceuticals Corporation | $378.19 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $361.11 | 2022-2024 | Austedo Xr, Austedo |
| Amarin Pharma, INC. | $298.43 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $277.94 | 2021-2024 | Farxiga, Fasenra |
| Exact Sciences Corporation | $187.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $156.89 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $154.33 | 2025 | Korlym |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.